This article has been updated with additional details on the coverage criteria of the LCD.

NEW YORK (GenomeWeb) – Genomic Health today announced that Medicare contractor Palmetto GBA has issued a draft local coverage determination for its Oncotype DX prostate cancer test.

The draft LCD recommends coverage of the test for qualified Medicare patients "to help determine which patients with early-stage, needle biopsy proven prostate cancer can be conservatively managed rather than treated with definitive surgery or radiation therapy."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.